MBX Biosciences (MBX) Minority Interest (2023 - 2024)

MBX Biosciences (MBX) posted Minority Interest of $115.9 million for Q2 2024, up 217.41% sequentially from $36.5 million in Q1 2024.

Analysis

MBX Biosciences (MBX) Minority Interest (2023 - 2024) Analysis & Trends

MBX Biosciences has reported Minority Interest for 2 years, with the latest figure at $115.9 million in Q2 2024.

Quarterly Minority Interest changed N/A year-over-year to $115.9 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $115.9 million (changed N/A YoY) and the FY2023 annual result came in at $36.5 million, changed N/A from the prior year.
Minority Interest climbed to $115.9 million in Q2 2024 per MBX's latest filing, from $36.5 million in the prior quarter.
Over five years, Minority Interest peaked at $115.9 million in Q2 2024 and troughed at $36.5 million in Q3 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	MBX Biosciences	2.97 Bn	2.97 Bn	-

Historic Data

Download Data